27 Drydock Avenue
177 articles with Ginkgo Bioworks
Ginkgo Bioworks Holdings, Inc. today announced the sale of shares of its Class A common stock for gross proceeds of approximately $100 million to BTIG, LLC, as the underwriter in the registered public offering of those shares.
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo"),which is building the leading platform for cell programing and biosecurity, today announced that it intends to offer and sell $100 million of its Class A common stock in an underwritten public offering.
Ginkgo Bioworks Holdings, Inc., which is building the leading platform for cell programming and biosecurity, announced its results for the third quarter ended September 30, 2022.
Lygos and Ginkgo Bioworks Announce Partnership to Optimize Production of Biobased Specialty Chemicals
Lygos, Inc. and Ginkgo Bioworks today announced a multi-product research and development collaboration designed to optimize and scale production of sustainable specialty ingredients that can replace toxic petrochemistry, reclaim local manufacturing, and advance industrial bio-innovation.
Ginkgo Bioworks To Present New Data on High Throughput Pooled Screening Method to Discover Novel CAR-T Designs for Solid Tumors
Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced that it will be presenting a poster on November 11 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that it plans to host a presentation and Q&A session reviewing business performance for the third quarter ended September 30, 2022, on Monday, November 14, 2022, beginning at 4:30 p.m. ET.
Ginkgo Bioworks and the Ministry of Investment of Saudi Arabia Announce Plans to Develop Biosecurity and Biotechnology Capabilities for Global Public Health
Ginkgo Bioworks and the Ministry of Investment of Saudi Arabia today announced that they have entered into a non-binding Memorandum of Understanding with the intent of developing biotechnology and biosecurity capabilities to deploy new public health initiatives in the Kingdom of Saudi Arabia.
Bolt Threads today announced a multi-project collaboration to increase the production efficiency and performance of Bolt's current portfolio as well as expand it by developing novel proteins for biomaterials.
Today, Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and Zymergen (Nasdaq: ZY) announced that Ginkgo has completed its previously announced acquisition of Zymergen.
The Intelligence Advanced Research Projects Activity (IARPA) and Ginkgo Bioworks today announced the completion of IARPA's Finding Engineering-Linked Indicators (FELIX) program.
Incidence of gout - the most common inflammatory arthritis in the world - are on the rise. Arthrosi Therapeutics, Synlogic, Atom Bioscience and Ginkgo Bioworks are on the case with novel new approaches.
Ginkgo Bioworks Announces Collaboration with Merck to Improve Active Pharmaceutical Ingredient Manufacturing
Ginkgo Bioworks today announced a collaboration with Merck to engineer up to four enzymes for use as biocatalysts in Merck's active pharmaceutical ingredient (API) manufacturing efforts.
Ginkgo Bioworks partnered with Merck on engineered enzymes for use as biocatalysts for Merck's active pharmaceutical ingredient (API) manufacturing programs.
Ginkgo Bioworks today announced the tuck-in acquisition of Altar, a French biotechnology company that has developed a proprietary adaptive evolution platform.
Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the tuck-in acquisition of Circularis, a biotechnology company with a proprietary circular RNA and promoter screening platform.
Ginkgo Bioworks opened its wallet Tuesday and snapped up Circularis and Altar to strengthen its cell and gene therapy programs and bolster its manufacturing capabilities.
The White House announced that President Biden intends to appoint Renee Wegrzyn, PhD, as the first Director of the Advanced Research Projects Agency for Health.
President Joe Biden tapped Ginkgo Bioworks veteran Renee Wegrzyn to helm the recently-established Advanced Research Projects Agency for Health (ARPA-H).
Ginkgo Bioworks Appoints Dr. Behzad Mahdavi as Senior Vice President of Biopharma Manufacturing & Life Science Tools
Ginkgo Bioworks, the leading horizontal platform for cell programming, announced that Behzad Mahdavi, Ph.D., MBA, has joined as senior vice president of biopharma manufacturing and life sciences tools.
In an SEC filing, Zymergen revealed it was cutting 80 more jobs and parting with Zach Serber, its co-founder and chief scientific officer.